Open Access iconOpen Access

ARTICLE

crossmark

Vaccinia-related kinase 2 variants differentially affect breast cancer growth by regulating kinase activity

SEUNG-HEE GWAK1, JUHYUN LEE1, EUNJI OH1, DOHYUN LEE1,2, WONSHIK HAN3, JONGMIN KIM1,*, KYONG-TAI KIM4,*

1 Department of Life Sciences, Pohang University of Science and Technology, Pohang, 37673, Korea
2 R&D Center, NovMetaPharma Co., Ltd., Pohang, 37668, Korea
3 Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Korea
4 Generative Genomics Research Center, Global Green Research & Development Center, Handong Global University, Pohang, 37554, Korea

* Corresponding Authors: JONGMIN KIM. Email: email; KYONG-TAI KIM. Email: email,email

Oncology Research 2024, 32(2), 421-432. https://doi.org/10.32604/or.2023.031031

Abstract

Genetic information is transcribed from genomic DNA to mRNA, which is then translated into three-dimensional proteins. mRNAs can undergo various post-transcriptional modifications, including RNA editing that alters mRNA sequences, ultimately affecting protein function. In this study, RNA editing was identified at the 499th base (c.499) of human vaccinia-related kinase 2 (VRK2). This RNA editing changes the amino acid in the catalytic domain of VRK2 from isoleucine (with adenine base) to valine (with guanine base). Isoleucine-containing VRK2 has higher kinase activity than the valine-containing VRK2, which leads to an increase in tumor cell proliferation. Earlier we reported that VRK2 directly interacts with dystrobrevin-binding protein (dysbindin) and results in reducing its stability. Herein, we demonstrate that isoleucine-containing VRK2 decreases the level of dysbindin than valine-containing VRK2. Dysbindin interacts with cyclin D and thereby regulates its expression and function. The reduction in the level of dysbindin by isoleucine-containing VRK2 further enhances the cyclin D expression, resulting in increased tumor growth and reduction in survival rates. It has also been observed that in patient samples, VRK2 level was elevated in breast cancer tissue compared to normal breast tissue. Additionally, the isoleucine form of VRK2 exhibited a greater increase in breast cancer tissue. Therefore, it is concluded that VRK2, especially dependent on the 167th variant amino acid, can be one of the indexes of tumor progression and proliferation.

Graphical Abstract

Vaccinia-related kinase 2 variants differentially affect breast cancer growth by regulating kinase activity

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

APA Style
GWAK, S., LEE, J., OH, E., LEE, D., HAN, W. et al. (2024). Vaccinia-related kinase 2 variants differentially affect breast cancer growth by regulating kinase activity. Oncology Research, 32(2), 421-432. https://doi.org/10.32604/or.2023.031031
Vancouver Style
GWAK S, LEE J, OH E, LEE D, HAN W, KIM J, et al. Vaccinia-related kinase 2 variants differentially affect breast cancer growth by regulating kinase activity. Oncol Res. 2024;32(2):421-432 https://doi.org/10.32604/or.2023.031031
IEEE Style
S. GWAK et al., "Vaccinia-related kinase 2 variants differentially affect breast cancer growth by regulating kinase activity," Oncol. Res., vol. 32, no. 2, pp. 421-432. 2024. https://doi.org/10.32604/or.2023.031031



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 879

    View

  • 224

    Download

  • 1

    Like

Share Link